DF
MRTX

Donoghue Forlines’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Donoghue Forlines’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-10,260
Closed -$1.7M – 306
2020
Q3 		$1.7M Buy
+10,260
New +$1.4M 0.47% 27

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Donoghue Forlines's MRTX Position: Q4 2020 in Review

Donoghue Forlines sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2020, closing a stake of 10,260 shares — an estimated $1.7M sold.

Donoghue Forlines first reported a position in MRTX in Q3 2020 and held it in 1 quarter. The position peaked at $1.7M in Q3 2020. 284 funds tracked by Wall St. Rank hold MRTX as of Q4 2020.

  • Donoghue Forlines reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Donoghue Forlines sold 10,260 Mirati Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $1.7M.
  • Donoghue Forlines first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2020 and held it in 1 quarter.
  • Donoghue Forlines's Mirati Therapeutics, Inc. Common Stock position peaked at $1.7M in Q3 2020.
  • 284 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Donoghue Forlines's 13F filing for Q4 2020, filed 9 Feb 2021.